KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 628 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078]. PMID 41259940 · Eur J Cancer · 2026-Jan The record is a corrigendum to a safety analysis from a Phase III trial, not an original report of a primary/key secondary time-to-event efficacy endpoint. No efficacy data (e.g., OS, PFS, HR, Kaplan-Meier) are indicated in the provided metadata.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
An international placebo-controlled randomized multicenter trial of nimorazole with accelerated chemo-radiotherapy for locally advanced HPV-negative squamous cell carcinoma of the head and neck (HNSCC). PMID 41138857 · Radiother Oncol · 2026-Jan The study is a randomized, placebo-controlled, multicenter trial in human oncology patients with a drug intervention (nimorazole) and reports time-to-event efficacy outcomes (including HR). However, the abstract and metadata do not explicitly state the trial phase (e.g., Phase III, Phase II/III). Without explicit phase information, eligibility cannot be confirmed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
ASO Visual Abstract: Synergistic Effects of Psychological Resilience Training and Nutritional Support on Postoperative Recovery, Nutritional Reconstitution, Sleep Quality, and Long-term Survival in Gastric Cancer-A Randomized Controlled Trial. PMID 41057749 · Ann Surg Oncol · 2026-Jan The record lacks sufficient metadata to establish key criteria: no human subjects confirmation, no phase (Phase III/IIIb or II/III) confirmation, no drug-containing intervention (interventions are psychological/nutritional), no primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc., Kaplan-Meier, or HR) mentioned, and no confirmation of a primary result report. The title suggests a randomized trial in gastric cancer (oncology), but the core eligibility criteria are not met.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
[Bacterial decolonization with mupirocin ointment reduces severe radiation-induced oral mucositis in nasopharyngeal carcinoma: results of a randomized phase 3 trial]. PMID 41051489 · Strahlenther Onkol · 2026-Jan The record describes a randomized phase 3 trial in nasopharyngeal carcinoma (oncology) with a drug-containing intervention (mupirocin ointment), but the abstract provides no information on time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR data. The primary endpoint appears to be severe radiation-induced oral mucositis, which is a safety/toxicity endpoint, not a time-to-event efficacy endpoint. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort focused on time-to-event efficacy.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma. PMID 41378992 · Clin Cancer Res · 2026-Feb-17 The record describes a randomized, drug-intervention trial in human oncology with a time-to-event endpoint (PFS). However, two key criteria for eligibility cannot be definitively established from the provided metadata: 1) The formal trial phase (Phase III/IIIb or Phase II/III) is not explicitly stated in the title, abstract, or metadata, though the title mentions 'late-phase' and the abstract notes it as a completed efficacy trial. 2) The report is a secondary/biomarker analysis ('exploratory analysis') of the GOG281/LOGS trial, not the primary formal-result report of the trial's main efficacy findings. Therefore, is_eligible is set to null.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC). PMID 41640231 · Future Oncol · 2026-Feb The record is a plain language summary, not a formal results report. The abstract is empty, providing no data on the trial phase, human subjects, time-to-event endpoints, or original result details. The title indicates a randomized study (keyword: 'randomized controlled trial') with a drug intervention, but without a results abstract or full publication, eligibility criteria cannot be established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Feasibility and Implementation of INTERVAL-GAP4: A Global Randomised Controlled Trial of Intense Hybrid-supervised/Self-managed Versus Self-directed Exercise for Metastatic Prostate Cancer. PMID 41561488 · Eur Urol Open Sci · 2026-Feb The report is an original article about a Phase III randomized trial in metastatic prostate cancer. However, it is not eligible because: 1) The intervention is exercise-based, not a drug-containing intervention. 2) The primary efficacy outcomes (survival) are explicitly stated to be reported separately; this paper only reports feasibility and implementation. There is no time-to-event efficacy data (OS, PFS, etc.) presented.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Pesco-Vegetarian Food Components Promote Colonocyte Ferroptosis in Preclinical Mouse Models and a Randomized Crossover Trial in Healthy Human Adults. PMID 41461276 · J Nutr · 2026-Feb The study is an original randomized controlled trial, but it fails multiple key eligibility criteria: it is not a Phase III or Phase II/III trial, the intervention is not a drug (it is a dietary supplement), and the outcome is not a time-to-event efficacy endpoint. Therefore, it is excluded.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
MARGIN: Randomized Trial of Arterial CT Portography Versus Standard Imaging Guidance for Percutaneous Thermal Ablation of Colorectal Liver Metastases. PMID 41457158 · Cardiovasc Intervent Radiol · 2026-Feb This is a protocol manuscript for a randomized trial. The primary endpoint is complete ablation at 3 months (a radiological response measure), not a time-to-event endpoint like OS, PFS, etc. The intervention is procedural (imaging guidance for ablation), not a drug-containing intervention. The phase is not explicitly stated as Phase III or II/III. As a protocol without results, it does not meet the eligibility criteria for inclusion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK-β. PMID 41405367 · Adv Sci (Weinh) · 2026-Feb The study is a Phase III randomized trial in oncology with a drug intervention, but its primary reported outcome is pathological complete response (pCR) and correlative biomarker analysis of A20 expression. No time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or its statistical representation (e.g., Kaplan-Meier curves, HR) is reported or signaled in the title or abstract.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Bibliometric analysis of anti-angiogenic therapy in gastric cancer: research hotspots, trends, and emerging frontiers. PMID 41284207 · Int J Clin Pharm · 2026-Feb The record is a bibliometric review analyzing research trends, not an original clinical trial report. It lacks primary time-to-event efficacy data from a randomized trial.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Re: Metformin for Patients with Metastatic Prostate Cancer Starting Androgen Deprivation Therapy: A Randomised Phase 3 Trial of the STAMPEDE Platform Protocol. PMID 40925750 · Eur Urol · 2026-Feb Title indicates a randomized Phase 3 trial, but no abstract or text is provided to confirm a drug-containing intervention (e.g., metformin) and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). Cannot establish eligibility without explicit evidence of these criteria.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
[Medical tumor therapy for head and neck cancer: between standardization and personalization]. PMID 40261344 · HNO · 2026-Feb The record is a review article summarizing developments and mentioning results from multiple phase III studies, not an original formal-result report of a single randomized trial with a primary time-to-event endpoint.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Mixture cure model analysis of event-free survival in the NIAGARA Trial: Quantifying the cure fraction benefit of perioperative durvalumab in muscle-invasive bladder cancer. PMID 42247881 · Urol Oncol · 2026-Aug The record describes an exploratory statistical analysis (mixture cure model) of reconstructed individual patient data from the NIAGARA trial. The metadata (publication types, MeSH) indicates a 'Randomized Controlled Trial' but does not explicitly state the trial phase as Phase III/IIIb or Phase II/III. Furthermore, this is not an original formal-result report of the trial itself; it is a secondary analysis using reconstructed data to explore cure fractions. Therefore, while individual criteria (oncology, human, randomized, drug intervention, time-to-event) are met, the report is not an eligible original trial result.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Magnetic resonance imaging-based radiomics analysis: predicting vascular invasion in breast invasive ductal carcinoma using different machine learning models. PMID 42180954 · Transl Cancer Res · 2026-Apr-30 The record is a retrospective diagnostic/prognostic study evaluating MRI-based radiomics for predicting lymphovascular invasion in breast cancer. It is not a randomized clinical trial, does not assess a drug intervention, and does not report time-to-event efficacy outcomes.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma. PMID 42019971 · J Immunother Cancer · 2026-Apr-22 The study is a randomized Phase III trial in oncology with a drug intervention and reports original results, but it does not report a primary or key secondary time-to-event efficacy endpoint (such as OS, PFS, DFS, etc.) in the provided abstract. The focus is on biomarker and single-cell analysis of treatment response, not clinical survival outcomes.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013. PMID 42010655 · J Hematol Oncol · 2026-Apr-20 Eligibility criteria are met except for the explicit confirmation of a Phase III/IIIb or Phase II/III trial. The study is a randomized trial in human pediatric oncology with drug interventions and time-to-event endpoints (OS, EFS), presenting final comparative results. However, the phase is not explicitly declared in the provided information, and inference is not allowed per adjudication rules.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Protocol of a randomised controlled trial: comparing the safety and efficacy of two methadone conversion strategies in Chinese patients with cancer pain receiving high-dose opioids. PMID 41985948 · BMJ Open · 2026-Apr-15 This is a clinical trial protocol (not a results report) for a randomized trial in cancer pain. While it involves oncology patients, human subjects, randomization, and a drug intervention, it does not present primary or secondary results. The primary efficacy endpoint is time to stable analgesia (not a time-to-event survival endpoint like OS/PFS). No Kaplan-Meier or HR data are reported.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
[Effects of electroacupuncture on gastrointestinal dysfunction and serum metabolites in postoperative patients with gastric cancer]. PMID 41987440 · Zhongguo Zhen Jiu · 2026-Apr-12 The study is an oncology RCT in humans but is ineligible because the intervention is non-drug (electroacupuncture) and it lacks a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). PMID 41934038 · Eur Urol · 2026-Apr-02 The record is a letter to the editor responding to a previously published trial report. The title explicitly states 'Re:', and no abstract is provided to verify the necessary inclusion criteria. Therefore, it is not an original formal result report of a randomized trial.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Serum Biomarkers and CT-Derived Muscle Indices in Sarcopenia Associated with Pancreatic Neoplasm: A Comparative Clinical Study. PMID 42084250 · Chirurgia (Bucur) · 2026-Apr The study is a randomized prospective biomarker and imaging study comparing patients with pancreatic neoplasm and sarcopenia to controls. While it involves human oncology patients and has a randomized design, it does not contain a drug-containing intervention (it is an observational/diagnostic biomarker study) and does not report a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, etc. The study's focus is on diagnostic/prognostic biomarkers and sarcopenia assessment, not the efficacy of a therapeutic drug.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis. PMID 41689889 · Lung Cancer · 2026-Apr The report is a subset analysis (Asian participants) of the MARIPOSA trial. While the analysis itself has formal results, it is not the primary report of the Phase III/definitive trial; it is a secondary/subgroup analysis. The original MARIPOSA trial is likely Phase III (based on drug names and standard trial design for approval), but the report's own metadata does not explicitly confirm the phase of the MARIPOSA trial itself. Therefore, phase3_or_definitive cannot be confirmed from this record alone.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Participation in lung cancer biospecimen studies: an analysis of the ECOG-ACRIN phase 3 E1505 and E5508 clinical trials. PMID 41666849 · Lung Cancer · 2026-Apr The record is a secondary analysis of participation in biospecimen studies within two phase 3 lung cancer therapeutic trials. While the parent trials are oncology, human, randomized, phase 3, and drug-interventional, this specific publication does not report original trial efficacy results or any time-to-event endpoints. It focuses on factors associated with patient consent for biospecimen collection, making it a secondary/sociological analysis rather than a primary efficacy report eligible for Kaplan-Meier digitization.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Modified EXTREME regimen versus modified TPEx regimen as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, open-label, randomized, exploratory study (TEMPER study). PMID 41661417 · Int J Clin Oncol · 2026-Apr The study is an oncology, human, randomized trial with drug intervention and time-to-event endpoints (PFS, OS). However, the trial is explicitly described as an 'exploratory study' and no Phase III/IIIb or Phase II/III designation is provided in the title, abstract, or metadata. Phase cannot be inferred from the drug name or regimen comparison. Therefore, the critical phase3_or_definitive criterion is not established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Trajectory of Neurocognitive Functioning in Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana-Farber Cancer Institute ALL Consortium Study 16-001. PMID 41518030 · Pediatr Blood Cancer · 2026-Apr The study is an oncology Phase III clinical trial in humans with a drug-containing intervention, but it lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS with Kaplan-Meier or HR). The endpoint is neurocognitive functioning, which is a secondary/safety outcome, not a primary efficacy endpoint as required for inclusion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
RESECT: A Randomised Controlled Trial of Audit and Feedback in Non-muscle-invasive Bladder Cancer Surgery. PMID 41444076 · Eur Urol · 2026-Apr The trial is oncology, human, randomized, and includes a drug intervention (single-instillation chemotherapy) with an original result. However, it is not a Phase III/IIIb or definitive Phase II/III trial (publication type is RCT but phase not specified, and study design is a cluster randomized quality improvement trial, not a drug efficacy trial). Furthermore, the primary endpoints are surgical performance metrics and early recurrence rate (reported as odds ratio), not a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A cost comparison of radiotherapy and topical imiquimod for lentigo maligna treatment: Considerations for clinical decision-making. PMID 41421462 · J Am Acad Dermatol · 2026-Apr The record is a cost-comparison study based on a referenced Phase III randomized trial, but it is not a report of the trial's primary or key secondary time-to-event efficacy endpoint. The abstract focuses on economic outcomes, not survival or progression metrics.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Re: Niraparib and Abiraterone Acetate plus Prednisone for HRR-deficient Metastatic Castration-sensitive Prostate Cancer: A Randomized Phase 3 Trial. PMID 41407561 · Eur Urol · 2026-Apr The record describes a relevant Phase 3 randomized trial protocol but provides no reported results, including no time-to-event efficacy endpoint data, preventing classification as an eligible original result report.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Impact of Testosterone Replacement Therapy on Functional and Oncological Outcomes Following Radical Prostatectomy (ENFORCE Study). PMID 40514343 · Eur Urol Oncol · 2026-Apr The record describes a Phase 3, randomized, placebo-controlled trial of testosterone replacement therapy in prostate cancer patients, with an oncological component (biochemical recurrence). However, it is a protocol/registration document without formal results. Furthermore, the primary endpoint is a patient-reported outcome (sexual function), not a time-to-event efficacy endpoint. While biochemical recurrence is mentioned, the abstract does not specify it as a primary or key secondary endpoint for time-to-event analysis (e.g., Kaplan-Meier or hazard ratio), and no results are presented. Therefore, it does not meet the criteria for a definitive Phase III result report with a time-to-event efficacy endpoint.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
CT Perfusion Blood Flow Provides an Early Response Marker for Progression-free Survival in a Prospective Randomized Clinical Trial of Metastatic Renal Cell Carcinoma. PMID 42308169 · Technol Cancer Res Treat · 2026 The record is from a randomized trial in oncology with a time-to-event endpoint and drug intervention, but the specific analysis described is secondary, focusing on a biomarker (CT perfusion blood flow) as a predictor of PFS, not the primary report of the drug efficacy trial. The phase (III/IIIb or II/III) is not explicitly stated in the provided metadata, preventing definitive eligibility.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Impact of early blood purification on serum inflammatory mediators and hemorheology in severe acute pancreatitis. PMID 41024315 · Hereditas · 2025-Sep-29 The study is a randomized trial in humans with a primary clinical endpoint, but it is not an oncology study (severe acute pancreatitis). The intervention is a non-drug procedure (blood purification/hemodiafiltration). No time-to-event efficacy endpoint (OS, PFS, etc.) or Kaplan-Meier/HR analysis is reported.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast Cancer. PMID 40763319 · J Clin Oncol · 2025-Sep-10 The report meets criteria for oncology, human, randomized, time-to-event endpoint, drug intervention, and original result. However, the phase of the trial (Phase III/IIIb or Phase II/III) is not explicitly established in the provided metadata, making eligibility indeterminate.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Factors influencing locoregional recurrence rates in locally advanced rectal cancer after total neoadjuvant treatment versus chemoradiotherapy in the RAPIDO trial. PMID 41020329 · Br J Surg · 2025-Sep-02 The record is an original result report from a randomized Phase III trial (RAPIDO) in oncology with a drug intervention and a primary time-to-event endpoint (locoregional recurrence). Although the abstract focuses on subgroup analysis (sphincter-preserving vs. abdominoperineal resection), it reports results from the overall trial population and is not exclusively a post-hoc, biomarker, QoL, safety, or economic analysis. The abstract confirms the randomized, Phase III nature of the trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Physical fitness and clinically assessed disease burden in long-term childhood cancer survivors-The SURfit study. PMID 40831029 · Cancer · 2025-Sep-01 The study is a randomized trial in human cancer survivors, but it is not a Phase III trial with a drug intervention. The primary endpoint is disease burden (adverse health outcomes) and its association with physical fitness, not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, or TTP. The intervention is physical activity/exercise, not a drug.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and safety of hyperthermic intraperitoneal intraoperative chemotherapy plus surgery in advanced ovarian cancer patients. PMID 40925342 · J Int Med Res · 2025-Sep The study is an oncology randomized trial with human subjects and reports primary time-to-event efficacy results (OS, PFS). However, the intervention (HIPEC) is not a systemic drug-containing intervention as required by the inclusion criteria; it is a locoregional/intraoperative procedure. The phase (Phase III/IIIb or II/III) is not explicitly established in the provided metadata. Therefore, it is excluded due to the absence of a qualifying drug intervention, making it ineligible for the specific cohort.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Artificial Intelligence-Based Multimodal Prediction of Postoperative Adjuvant Immunotherapy Benefit in Urothelial Carcinoma: Results From the Phase III, Multicenter, Randomized, IMvigor010 Trial. PMID 40859961 · MedComm (2020) · 2025-Sep This is a secondary, post-hoc biomarker analysis from the primary IMvigor010 trial, focused on developing an AI-based predictive score. The abstract does not present primary time-to-event efficacy results (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) from the trial itself, but rather discusses the predictive performance of the UAIscore in stratifying patients.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors. PMID 40318924 · Int J Gynecol Cancer · 2025-Sep This is a phase 1b/2 trial protocol without results, not a Phase III/IIIb or Phase II/III randomized trial. The primary endpoints are safety and objective response rate (ORR), not a primary/key secondary time-to-event efficacy endpoint like OS, PFS, DFS, etc. The trial is ongoing with results expected in 2026, so it is a protocol without results, not an original formal result report.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Real-World Evidence: A Randomized, Controlled, Single-Blinded Trial Comparing Oral Sulfate Tablets Versus PEG Formulations for Bowel Preparation Before Colonoscopy. PMID 42425913 · J Clin Gastroenterol · 2025-Oct-30 The record describes a randomized, single-blinded non-inferiority trial of bowel preparation formulations (oral sulfate tablets vs. PEG) for colonoscopy in patients needing screening/surveillance for colorectal cancer. The study's primary endpoints are cleansing efficacy (scored by an FDA scale), tolerability, and adverse events. It does not have an oncology-specific Phase III/IIIb or Phase II/III design, a drug-containing intervention for treating a malignant neoplasm, or a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR analysis.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A Randomized Controlled Trial of Stereotactic Body Radiation Therapy Versus Chemoradiation Following Induction Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. PMID 41144077 · J Gastrointest Cancer · 2025-Oct-27 The record is a randomized, prospective, human oncology trial with time-to-event endpoints and drug intervention, but the abstract does not explicitly state the trial phase (e.g., Phase II or III). Metadata cannot confirm the required phase criterion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Preoperative Prediction of Axillary Lymph Node Metastasis in Breast Cancer Using Radiomics Features of Voxel-Wise DCE-MRI Time-Intensity-Curve Profile Maps. PMID 41153841 · Biomedicines · 2025-Oct-21 The study is a retrospective diagnostic/radiomics analysis to predict axillary lymph node metastasis in breast cancer. It is not a randomized trial, does not involve a drug intervention, and does not have a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, Kaplan-Meier, HR).
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Community-Engaged Approach to Increase Physical Activity Among Black Individuals With Colorectal Cancer: Protocol for a Feasibility Randomized Controlled Trial of the Physical Activity Centers Empowerment Study. PMID 41105939 · JMIR Res Protoc · 2025-Oct-17 This is a protocol for a feasibility randomized controlled trial of a behavioral (physical activity) intervention. It does not present efficacy results, lacks a time-to-event primary endpoint, and has no drug intervention. It is not a Phase III/IIIb or Phase II/III report.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Targeting the glucocorticoid receptor as a therapeutic strategy for ovarian cancer: The ROSELLA study. PMID 41075778 · Med · 2025-Oct-10 The record is for an oncology, human, randomized trial with a drug intervention (relacorilant + nab-paclitaxel vs. nab-paclitaxel) and a primary time-to-event endpoint (PFS, OS). It is an original result report. However, the explicit trial phase (Phase III/IIIb or Phase II/III) is not established in the provided metadata (title, abstract, publication types, MeSH), making the 'phase3_or_definitive' criterion unverifiable. Therefore, overall eligibility is set to null.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML. PMID 40768751 · Blood · 2025-Oct-09 The record describes a randomized, oncology trial with a drug intervention and original results, but lacks an explicit Phase III/IIIb designation and does not specify a time-to-event endpoint in the provided abstract, making it ineligible under the strict criteria.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Clinical Significance of a Multicancer Screening Trial With Stage-Based End Points. PMID 41066125 · JAMA Netw Open · 2025-Oct-01 The study is an independent decision-analytic model estimating outcomes of a planned screening trial, not a clinical trial report. It does not involve a drug intervention, and its outcomes (late-stage incidence reductions, mortality reductions over fixed periods) are not time-to-event endpoints in the required sense. The trial phase is not specified.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A machine learning approach for radiation pneumonitis prediction in elderly esophageal cancer patients by integrating baseline computed tomography radiomics, dosiomics, and clinical characteristics. PMID 41333544 · Phys Imaging Radiat Oncol · 2025-Oct This is a secondary predictive modeling study based on a Phase III trial, not a primary report of the trial's efficacy results. The endpoint is a toxicity (radiation pneumonitis), not a time-to-event efficacy endpoint (OS, PFS, etc.). No drug intervention is described.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Qu-yu-jie-du decoction maintenance therapy improves postoperative survival in metastatic colorectal cancer: a single-center randomized trial with 36-month follow-up. PMID 40815944 · Phytomedicine · 2025-Oct The record is an original result report of a randomized trial in oncology with a drug intervention and a key time-to-event efficacy endpoint (DFS). However, the explicit trial phase is not provided in the title, abstract, or metadata. It is described as a 'single-center randomized trial' without specifying Phase II, III, or other. The deterministic review flagged 'phase3_evidence_unclear' as the reason for needing review. Without explicit confirmation of a Phase III/IIIb or Phase II/III trial, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1. PMID 40473108 · J Thorac Oncol · 2025-Oct The record is a randomized trial in human oncology with a drug intervention and a time-to-event endpoint (treatment-free survival). However, the phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata. Additionally, while the endpoint is time-to-event and derived from KM curves, it is treatment-free survival, which is not one of the primary/key secondary endpoints listed in the criteria (OS, PFS, DFS, EFS, RFS, TTP). Therefore, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial. PMID 40348701 · Eur Urol · 2025-Oct The record describes a phase 3 randomized trial of a surgical technique (NeuroSAFE-guided vs standard RARP) for localized prostate cancer. While it meets criteria for oncology, human, randomized, and phase 3, it lacks a drug-containing intervention and does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) or Kaplan-Meier/HR data, focusing instead on functional outcomes.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
CAMONCO 2: Results From a Randomized Controlled Trial Comparing Open Dialogue About Complementary Alternative Medicine and Standard Care on Patients' Quality of Life. PMID 39700437 · JCO Oncol Pract · 2025-Oct The trial is randomized and oncology-focused with a time-to-event endpoint (overall survival), but it lacks explicit confirmation of Phase III/IIIb or Phase II/III, and the intervention (Open Dialogue About Complementary Alternative Medicine) is not a pharmacologic drug intervention, which is required for inclusion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy analysis of TACE in combination with anlotinib and sintilimab in the treatment of unresectable hepatocellular carcinoma. PMID 41286133 · Sci Rep · 2025-Nov-24 The record describes a randomized, controlled trial in oncology (hepatocellular carcinoma) with drug interventions (anlotinib, sintilimab) and time-to-event efficacy endpoints (PFS, OS). However, the trial phase is not explicitly stated in the title, abstract, or metadata as Phase III/IIIb or Phase II/III, which is a required criterion. Additionally, while time-to-event outcomes are reported, the abstract does not provide Kaplan-Meier curves or hazard ratios, which are key for digitization. Therefore, eligibility cannot be confirmed due to missing explicit phase evidence.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -